Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals.
Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals.
复制标题
DOI：
10.1016/j.celrep.2021.109570
复制
发表时间：
2021-08-24
期刊：
影响因子：
8.8
通讯作者：
Ochando J
中科院分区：
文献类型：
--
作者：
Lozano-Ojalvo D;Camara C;Lopez-Granados E;Nozal P;Del Pino-Molina L;Bravo-Gallego LY;Paz-Artal E;Pion M;Correa-Rocha R;Ortiz A;Lopez-Hoyos M;Iribarren ME;Portoles J;Rojo-Portoles MP;Ojeda G;Cervera I;Gonzalez-Perez M;Bodega-Mayor I;Montes-Casado M;Portoles P;Perez-Olmeda M;Oteo J;Sanchez-Tarjuelo R;Pothula V;Schwarz M;Brahmachary M;Tan AT;Le Bert N;Berin C;Bertoletti A;Guccione E;Ochando J
针对严重急性呼吸综合征冠状病毒-2(SARS-CoV-2)的基于mRNA的疫苗的快速发展导致了加速接种计划的设计，这些计划对幼稚的人非常有效。虽然BNT162b2疫苗的两剂免疫方案已被证明对幼稚的人提供95%的有效率，但第二剂疫苗对以前从自然SARS-CoV-2感染中康复的人的影响尚未得到详细调查。在这项研究中，我们研究了在接种两剂BNT162b2疫苗期间和接种两剂BNT162b2疫苗后，幼稚和先前感染的人的SARS-CoV-2刺激性体液和细胞免疫的特征。我们的结果表明，虽然第二次接种同时提高了幼稚个体的体液免疫和细胞免疫，但新冠肺炎恢复的个体在第一次接种后达到了免疫高峰。这些结果表明，根据目前的标准疫苗接种方案，以前感染过SARS-CoV-2的人可能没有必要接种第二剂疫苗。稀缺的SARS-CoV-2疫苗供应正在影响一些国家的疫苗接种政策。Lozano-Ojalvo等人。报道称，既往接触过SARS-CoV-2的受试者在接种第一剂BNT162b2疫苗后产生强烈的免疫反应，建议新冠肺炎康复个体采用单一疫苗接种方案。
The rapid development of mRNA-based vaccines against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) led to the design of accelerated vaccination schedules that have been extremely effective in naive individuals. While a two-dose immunization regimen with the BNT162b2 vaccine has been demonstrated to provide a 95% efficacy in naive individuals, the effects of the second vaccine dose in individuals who have previously recovered from natural SARS-CoV-2 infection has not been investigated in detail. In this study, we characterize SARS-CoV-2 spike-specific humoral and cellular immunity in naive and previously infected individuals during and after two doses of BNT162b2 vaccination. Our results demonstrate that, while the second dose increases both the humoral and cellular immunity in naive individuals, COVID-19 recovered individuals reach their peak of immunity after the first dose. These results suggests that a second dose, according to the current standard regimen of vaccination, may be not necessary in individuals previously infected with SARS-CoV-2. Scarce SARS-CoV-2 vaccine supplies are influencing vaccination policies in some countries. Lozano-Ojalvo et al. report that subjects with previous exposure to SARS-CoV-2 mount powerful immune responses after the first BNT162b2 vaccine dose, suggesting single vaccination regimens in COVID-19 recovered individuals.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
82.9
作者：
Ebinger JE;Fert-Bober J;Printsev I;Wu M;Sun N;Prostko JC;Frias EC;Stewart JL;Van Eyk JE;Braun JG;Cheng S;Sobhani K
通讯作者：
Sobhani K
影响因子：
8.8
作者：
Grupper, Ayelet;Rabinowich, Liane;Katchman, Helena
通讯作者：
Katchman, Helena
DOI：
10.1016/j.medj.2021.04.003
发表时间：
2021-06-11
期刊：
Med (New York, N.Y.)
影响因子：
--
作者：
Kalimuddin S;Tham CYL;Qui M;de Alwis R;Sim JXY;Lim JME;Tan HC;Syenina A;Zhang SL;Le Bert N;Tan AT;Leong YS;Yee JX;Ong EZ;Ooi EE;Bertoletti A;Low JG
通讯作者：
Low JG
DOI：
10.1084/jem.20202617
发表时间：
2021-05-03
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Le Bert N;Clapham HE;Tan AT;Chia WN;Tham CYL;Lim JM;Kunasegaran K;Tan LWL;Dutertre CA;Shankar N;Lim JME;Sun LJ;Zahari M;Tun ZM;Kumar V;Lim BL;Lim SH;Chia A;Tan YJ;Tambyah PA;Kalimuddin S;Lye D;Low JGH;Wang LF;Wan WY;Hsu LY;Bertoletti A;Tam CC
通讯作者：
Tam CC